Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Changes of O6-Methylguanine DNA Methyltransferase (MGMT) Promoter Methylation in Glioblastoma Relapse-A Meta-Analysis Type Literature Review.

Feldheim J, Kessler AF, Monoranu CM, Ernestus RI, Löhr M, Hagemann C.

Cancers (Basel). 2019 Nov 21;11(12). pii: E1837. doi: 10.3390/cancers11121837. Review.

2.

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R.

Clin Cancer Res. 2004 Mar 15;10(6):1871-4.

3.

MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?

Yamashita S, Yokogami K, Matsumoto F, Saito K, Mizuguchi A, Ohta H, Takeshima H.

J Neurosurg. 2018 May 4;130(3):780-788. doi: 10.3171/2017.11.JNS171710.

PMID:
29726772
4.

O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.

Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M.

Neuro Oncol. 2010 Mar;12(3):283-8. doi: 10.1093/neuonc/nop050. Epub 2010 Feb 1.

5.

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.

Lechapt-Zalcman E, Levallet G, Dugué AE, Vital A, Diebold MD, Menei P, Colin P, Peruzzy P, Emery E, Bernaudin M, Chapon F, Guillamo JS.

Cancer. 2012 Sep 15;118(18):4545-54. doi: 10.1002/cncr.27441. Epub 2012 Feb 22.

6.

Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.

Pyko IV, Nakada M, Sabit H, Teng L, Furuyama N, Hayashi Y, Kawakami K, Minamoto T, Fedulau AS, Hamada J.

Carcinogenesis. 2013 Oct;34(10):2206-17. doi: 10.1093/carcin/bgt182. Epub 2013 May 28.

PMID:
23715499
7.

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.

Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D.

Cancer. 2009 Oct 15;115(20):4783-94. doi: 10.1002/cncr.24546.

8.

The Impact of MGMT Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma.

Jovanović N, Mitrović T, Cvetković VJ, Tošić S, Vitorović J, Stamenković S, Nikolov V, Kostić A, Vidović N, Krstić M, Jevtović-Stoimenov T, Pavlović D.

Medicina (Kaunas). 2019 Feb 1;55(2). pii: E34. doi: 10.3390/medicina55020034.

9.

Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?

Tanaka S, Akimoto J, Narita Y, Oka H, Tashiro T.

J Neurosurg. 2014 Oct;121(4):818-26. doi: 10.3171/2014.6.JNS132535. Epub 2014 Aug 8.

PMID:
25105699
10.

Glioblastoma Recurrence and the Role of O6-Methylguanine-DNA Methyltransferase Promoter Methylation.

Storey K, Leder K, Hawkins-Daarud A, Swanson K, Ahmed AU, Rockne RC, Foo J.

JCO Clin Cancer Inform. 2019 Feb;3:1-12. doi: 10.1200/CCI.18.00062.

11.

Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.

Costa BM, Caeiro C, Guimarães I, Martinho O, Jaraquemada T, Augusto I, Castro L, Osório L, Linhares P, Honavar M, Resende M, Braga F, Silva A, Pardal F, Amorim J, Nabiço R, Almeida R, Alegria C, Pires M, Pinheiro C, Carvalho E, Lopes JM, Costa P, Damasceno M, Reis RM.

Oncol Rep. 2010 Jun;23(6):1655-62.

PMID:
20428822
12.

O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma.

Bobola MS, Alnoor M, Chen JY, Kolstoe DD, Silbergeld DL, Rostomily RC, Blank A, Chamberlain MC, Silber JR.

BBA Clin. 2015 Jun 1;3:1-10.

13.

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.

Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.

Pediatr Blood Cancer. 2007 Apr;48(4):403-7.

PMID:
16609952
14.

MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.

Grossman R, Burger P, Soudry E, Tyler B, Chaichana KL, Weingart J, Olivi A, Gallia GL, Sidransky D, Quiñones-Hinojosa A, Ye X, Brem H.

J Clin Neurosci. 2015 Dec;22(12):1938-42. doi: 10.1016/j.jocn.2015.07.003. Epub 2015 Aug 4.

PMID:
26249244
15.
16.

The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis.

Zhang K, Wang XQ, Zhou B, Zhang L.

Fam Cancer. 2013 Sep;12(3):449-58. doi: 10.1007/s10689-013-9607-1.

PMID:
23397067
17.

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.

Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW.

PLoS One. 2011 Feb 18;6(2):e17156. doi: 10.1371/journal.pone.0017156.

18.

O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.

Silber JR, Bobola MS, Blank A, Chamberlain MC.

Biochim Biophys Acta. 2012 Aug;1826(1):71-82. doi: 10.1016/j.bbcan.2011.12.004. Epub 2012 Jan 8. Review.

19.

Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.

Yuan G, Niu L, Zhang Y, Wang X, Ma K, Yin H, Dai J, Zhou W, Pan Y.

J Neurooncol. 2017 May;133(1):193-201. doi: 10.1007/s11060-017-2433-9. Epub 2017 May 17.

PMID:
28516344
20.

The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis.

Zhao YH, Wang ZF, Cao CJ, Weng H, Xu CS, Li K, Li JL, Lan J, Zeng XT, Li ZQ.

Front Neurol. 2018 Mar 21;9:127. doi: 10.3389/fneur.2018.00127. eCollection 2018.

Supplemental Content

Support Center